Skip to main content
Erschienen in: Supportive Care in Cancer 2/2020

08.06.2019 | Original Article

Factors impacting on discordance with treatment plan in head and neck cancer patients: a retrospective, population-based cohort study

verfasst von: Ya-Lan Chang, Shu-Chu Lee, Chun-Ta Liao, Chao-Hui Wang, Yu-Fen Lin, Shu-Ching Chen

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aims of this study were to identify the factors and reasons impacting discordance with the treatment plan in head and neck cancer (HNC) patients and compare the differences between the concordance group and the discordance group.

Methods

This secondary analysis was conducted from population-based data from Taiwan collected from January 1, 2016, to June 30, 2018. Logistic regression analysis was used to identify the factors related to discordance with the treatment plan.

Results

We examined 1095 HNC patients, 12.1% of whom were discordant with treatment. Patients with advanced cancer stage, old age, and treatment plans of best supportive care (BSC) or surgery combined with radiation (RT), chemotherapy (CT), or chemoradiation (CCRT) were more likely to have discordance with their treatment plan. Of the 133 patients who were discordant with their treatment plan, the top reasons were as follows: “patients or their family considered patients’ poor physical condition (chronic disease or unstable systemic disease), difficulty in enduring any condition likely to cause physical discomfort from disease treatment,” “inconvenient transportation,” and “disease progression.”

Conclusions

Patients’ cancer stage, age, and types of treatment plans recommended significantly influenced discordance with treatment plan. Poor physical condition was the major reason for discordance with the treatment plan. Patients in the concordance group were significantly more likely than those in the discordance group to be younger than 65 years, have less advanced cancer stage, and be recommended to receive surgery rather than any other regimen. Multidisciplinary team care can help patients make positive decisions about treatment.
Literatur
2.
5.
Zurück zum Zitat Latter S, Maben J, Myall M, Young A (2007) Perceptions and practice of concordance in nurses’ prescribing consultations: findings from a national questionnaire survey and case studies of practice in England. Int J Nurs Stud 44:9–18CrossRef Latter S, Maben J, Myall M, Young A (2007) Perceptions and practice of concordance in nurses’ prescribing consultations: findings from a national questionnaire survey and case studies of practice in England. Int J Nurs Stud 44:9–18CrossRef
6.
Zurück zum Zitat Horne R, Weinman J, Barber N et al (2005) Concordance, adherence and compliance in medicine taking. UK: National Coordinating Centre for NHS Service Delivery and Organization R and D. 1–309 Horne R, Weinman J, Barber N et al (2005) Concordance, adherence and compliance in medicine taking. UK: National Coordinating Centre for NHS Service Delivery and Organization R and D. 1–309
7.
Zurück zum Zitat Medicines Partnership (2003) Project evaluation toolkit. Medicines Partnership, London Medicines Partnership (2003) Project evaluation toolkit. Medicines Partnership, London
15.
Zurück zum Zitat Liao CT, Kang CJ, Lee LY, Hsueh C, Lin CY, Fan KH, Wang HM, Ng SH, Lin CH, Tsao CK, Fang TJ, Huang SF, Chang KP, Chang YL, Yang LY, Yen TC (2016) Association between multidisciplinary team care approach and survival rates in patients with oral cavity squamous cell carcinoma. Head Neck 38:E1544–E1553. https://doi.org/10.1002/hed.24276 CrossRefPubMed Liao CT, Kang CJ, Lee LY, Hsueh C, Lin CY, Fan KH, Wang HM, Ng SH, Lin CH, Tsao CK, Fang TJ, Huang SF, Chang KP, Chang YL, Yang LY, Yen TC (2016) Association between multidisciplinary team care approach and survival rates in patients with oral cavity squamous cell carcinoma. Head Neck 38:E1544–E1553. https://​doi.​org/​10.​1002/​hed.​24276 CrossRefPubMed
18.
Zurück zum Zitat Ivanics T, Proctor E, Chen Y, Ali H, Severson D, Nasser H, Colbert S, Susick L, Walker E, Petersen L, Bensenhaver J, Loutfi R, Nathanson SD, Newman LA (2019) Evaluation of a multidisciplinary team approach for generating survivorship care plan treatment summaries in patients with breast cancer [Epub ahead of print April 4, 2019]. J Oncol Pract 15:e467–e474. https://doi.org/10.1200/JOP.18.00509 CrossRefPubMed Ivanics T, Proctor E, Chen Y, Ali H, Severson D, Nasser H, Colbert S, Susick L, Walker E, Petersen L, Bensenhaver J, Loutfi R, Nathanson SD, Newman LA (2019) Evaluation of a multidisciplinary team approach for generating survivorship care plan treatment summaries in patients with breast cancer [Epub ahead of print April 4, 2019]. J Oncol Pract 15:e467–e474. https://​doi.​org/​10.​1200/​JOP.​18.​00509 CrossRefPubMed
23.
Zurück zum Zitat Koedoot CG, Oort FJ, de Haan RJ et al (2004) The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are. Palliative chemotherapy and watchful-waiting. Eur J Cancer 40:225e235CrossRef Koedoot CG, Oort FJ, de Haan RJ et al (2004) The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are. Palliative chemotherapy and watchful-waiting. Eur J Cancer 40:225e235CrossRef
24.
Zurück zum Zitat Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C (2008) Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26:1698–1704. https://doi.org/10.1200/JCO.2006.09.9887 CrossRefPubMed Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C (2008) Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26:1698–1704. https://​doi.​org/​10.​1200/​JCO.​2006.​09.​9887 CrossRefPubMed
27.
Zurück zum Zitat Handschel J, Gellrich NC, Bremerich A, Krüskemper G (2013) Return to work and quality of life after therapy and rehabilitation in oral cancer. In Vivo 27:401–407PubMed Handschel J, Gellrich NC, Bremerich A, Krüskemper G (2013) Return to work and quality of life after therapy and rehabilitation in oral cancer. In Vivo 27:401–407PubMed
29.
Zurück zum Zitat Agarwal J, Krishnatry R, Chaturvedi P, Ghosh-Laskar S, Gupta T, Budrukkar A, Murthy V, Deodhar J, Nair D, Nair S, Dikshit R, D’Cruz AK (2017) Survey of return to work of head and neck cancer survivors: a report from a tertiary cancer center in India. Head Neck 39:893–899. https://doi.org/10.1002/hed.24703 CrossRefPubMed Agarwal J, Krishnatry R, Chaturvedi P, Ghosh-Laskar S, Gupta T, Budrukkar A, Murthy V, Deodhar J, Nair D, Nair S, Dikshit R, D’Cruz AK (2017) Survey of return to work of head and neck cancer survivors: a report from a tertiary cancer center in India. Head Neck 39:893–899. https://​doi.​org/​10.​1002/​hed.​24703 CrossRefPubMed
Metadaten
Titel
Factors impacting on discordance with treatment plan in head and neck cancer patients: a retrospective, population-based cohort study
verfasst von
Ya-Lan Chang
Shu-Chu Lee
Chun-Ta Liao
Chao-Hui Wang
Yu-Fen Lin
Shu-Ching Chen
Publikationsdatum
08.06.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 2/2020
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-04904-z

Weitere Artikel der Ausgabe 2/2020

Supportive Care in Cancer 2/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.